PhotoCure Metvix approval
FDA will finish reviewing the Metvix (methyl amniolevulinate) NDA for actinic keratoses no later than July 27, PhotoCure says. An FDA advisory committee voted against approval of the phototherapy for the first-line treatment of basal cell carcinoma (1"The Pink Sheet" Sept. 15, 2003, p. 20). The NDA was later deemed "approvable," and PhotoCure submitted a safety update...
You may also be interested in...
PhotoCure's methyl aminolevulinate could be approved as part of a "niche" basal cell carcinoma phototherapy regimen for patients who are intolerant to other treatments, an FDA advisory committee said in voting against a broader indication
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.